Pegilodecakin
- Generic Name
- Pegilodecakin
- Drug Type
- Biotech
- CAS Number
- 1966111-35-2
- Unique Ingredient Identifier
- 5Z9850I25F
- Background
Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Prostate CancerPancreatic CarcinomaSolid TumorsBreast CancerMelanomaRenal Cell CarcinomaNon-small Cell Lung CarcinomaOvarian CancerColorectal Carcinoma
- Interventions
- Drug: Gemcitabine/carboplatinDrug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)Drug: gemcitabine/nab-paclitaxel
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 353
- Registration Number
- NCT02009449
- Locations
- 🇺🇸
UCLA Medical Hematology & Oncology, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath